Junshi Biosciences
Junshi Biosciences
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies
Junshi Biotech is a research and development company that focuses on the development of therapeutic antibodies. It has a wide range of technologies, including molecular antibody screening, construction of high-yield stable CHO cell lines and therapeutic antibody analysis and detection. As of the date of this prospectus, a total of 6 drugs have been formally established and are in the research and development stage, and the two drugs which are currently in rapid progress are recombinant humanized anti-PD-1 monoclonal antibody injection (JS001) and recombinant humanized anti-PCSK9 monoclonal antibody injection (JS002).
- All
- News
- Analysis
- Research
Briefing Jan 14, 2022 02:18 PM
· Healthcare
Hong Kong stocks continued to rise in the anti epidemic sector, and Junshi biology rose nearly 17%
Briefing Jan 04, 2022 11:32 PM
Junshi biological terminates its cooperation with AstraZeneca
In depth
Briefing Dec 31, 2021 01:08 PM
· Healthcare
Pharmaceutical and biological stocks continued to strengthen in the afternoon
Briefing Dec 27, 2021 09:49 AM
· Technology
The net purchase of 7 shares was more than 100 million yuan, and Ningde times was the most
Apr 22, 2021 03:11 PM
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Research
Real Estate, Industrials, FinancialsTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Dec 15, 2021 02:59 PM
· Healthcare
China Kexing: the positive rate of strengthening needle neutralization Omicron antibody reached 94%
Briefing Nov 19, 2021 04:49 PM
· Healthcare
Dima shares: the implementation of the third phase of the common growth plan has been completed, and a total of 36.1526 million shares have been purchased
In depth
Healthcare
Dada group's revenue rose nearly 30% in the third quarter, and JD's "hour purchase" cont
Looking forward to the fourth quarter of 2021, dada Group expects its total revenue to be between 2 billion yuan and 2.1 billion yuan. On the premise that the last kilometer of dada express delivery service is consistent with the comparable basis, the total revenue in the fourth quarter of 2021 will achieve a year-on-year increase of 88% to 97%.
Nov 24, 2021 11:42 AM
Junshi biology: js019 injection received the notice of acceptance of drug clinical trial application
Briefing Sep 02, 2021 10:27 AM
Junshi biological completed the rolling submission of the listing application of treprizumab for nasopharyngeal carcinoma to the FDA
Briefing Jan 27, 2021 05:59 PM
· Healthcare
Junshi biology announced that anti tigit monoclonal antibody js006 injection was approved for clinical trial.
See more
Related Companies
EqualOcean Analysis
- Wuxi Apptec Embraces a More Health-Conscious China
- Four Growing Stocks to Watch in the Dynamic Chinese Market
- Genetron Health's Self-Developed Mutation Capsule Differentiates It from Others
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.